Track ALT's AI-powered predictions, market trends, and investment insights.
StockTwits Mentions
823
ALT has been mentioned an estimated 823 times on StockTwits over the last 24 hours.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedAltimmune is currently unprofitable, as indicated by its negative EPS and PE ratio. The lack of positive earnings suggests that the company is still in a cash-burning, development-heavy phase, which raises risk for equity holders. Until there is a clear path to profitability or material revenue growth, the financial profile remains fundamentally weak.
Despite an 8.9% gain over the last month, Altimmune trades below its 200-day moving average, indicating a broader downtrend. The recent bounce appears more like a short-term recovery within a longer-term weak technical structure. Until the price can reclaim and hold above the 200-day moving average with improving fundamentals, the technical setup remains cautious to negative.
Alternative data for Altimmune is mixed but modestly constructive. Web traffic at roughly 104,021 visitors per month and a small uptick in LinkedIn followers suggest stable to slightly improving interest, while stagnant Twitter/X followers indicate limited retail or broad social buzz. The 33.3% month-over-month increase in job openings points to some internal growth or ramp-up, but from a low base and without clear confirmation of commercial traction.
Altimmune’s stock currently reflects a speculative, development-stage profile: negative earnings, a price below its 200-day moving average, and only modest alternative data strength. While there are early signs of operational activity and short-term price improvement, these are not yet strong enough to offset the structural risks of ongoing losses and a longer-term downtrend. Overall, the balance of evidence leans bearish until there is clearer progress toward profitability or decisive technical improvement.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
You don't hold ALT in your mock portfolio yet.
ALT StockTwits activity shows notable social engagement for Altimmune over the past seven days, with 3,679 mentions logged on the platform. That level of chatter places the stock firmly on the radar of retail traders monitoring small-cap biotech names. While StockTwits sentiment can shift quickly around clinical or regulatory catalysts, the sustained mention volume suggests traders are actively watching price levels and positioning around near-term developments. With ALT trading at $3.05, down 0.7% on the day, the conversation appears centered on whether the stock can hold support at current levels.
Context matters when interpreting ALT StockTwits volume. At 2,592,490 shares traded in the session and a market cap of $269.2 million, Altimmune sits in a range where retail sentiment can have an outsized influence on short-term price movement. The stock's AI Score of 5 out of 10 reflects a neutral-to-cautious fundamental and technical posture, suggesting the social buzz has not yet translated into a clear directional signal. Traders should weigh the elevated mention count against the modest price decline, as high social volume without corresponding price momentum can indicate indecision or accumulation rather than a confirmed trend.
TrendEdge aggregates ALT StockTwits data alongside Reddit mentions, which totaled just 5 over the same seven-day window, highlighting a sharp divergence between platform-specific audiences. By combining social mention volume, cross-platform sentiment, AI scoring, and price and volume data into a single dashboard, TrendEdge gives traders a structured way to separate noise from signal. Rather than relying on any single data source, the platform surfaces converging indicators to help users make more informed, evidence-based decisions around stocks like Altimmune.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
104,021
Twitter Followers
1,850
LinkedIn Followers
8,155
Job Postings
7
LinkedIn Employees
85
News Mentions
0
Key Metrics
